New drug duo aims to wipe out breast cancer before surgery

NCT ID NCT07383818

Recruiting now Disease control Sponsor: First Affiliated Hospital of Zhejiang University Source: ClinicalTrials.gov ↗

First seen Feb 03, 2026 · Last updated May 16, 2026 · Updated 14 times

Summary

This study tests two drugs, trastuzumab rezetecan and toripalimab, given before surgery to women with HR-positive, HER2-low breast cancer. The goal is to see if this combination can completely eliminate the cancer by the time of surgery. About 111 women aged 18-70 with early-stage but not metastatic disease will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Harbin Medical University Cancer Hospital
RECRUITING

Harbin, China

Contact
The First Affiliated Hospital of Anhui Medical University
RECRUITING

Hefei, China

Contact
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, China

Contact
The Second Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Zhengzhou, China

Contact
Zhongshan Hospital, Fudan University
RECRUITING

Shanghai, China

Contact

Conditions

Explore the condition pages connected to this study.

HR POSITIVE/HER2 LOW BREAST CANCER HR POSITIVE/HER2 LOW BREAST CANCER HR POSITIVE/HER2 LOW BREAST CANCER